Ocugen (OCGN) Free Cash Flow (2014 - 2026)
Ocugen's (OCGN) quarterly Free Cash Flow came in at -$21.8 million in Q1 2026, down 12.53% YoY from -$24.9 million in Q1 2025, and down 54.31% on a QoQ basis from -$14.1 million in Q4 2025.
Analysis
Ocugen (OCGN) Free Cash Flow (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Free Cash Flow data on file, last reported at -$21.8 million in Q1 2026.
- Quarterly Free Cash Flow fell 12.53% year-over-year to -$21.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.6 million (down 14.67% YoY) and the FY2025 annual result came in at -$57.1 million, down 25.53% from the prior year.
- Free Cash Flow slipped to -$21.8 million in Q1 2026, from -$14.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$5.7 million in Q4 2023 to a low of -$21.8 million in Q1 2026.
- A 5-year average of -$14.7 million and a median of -$14.4 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 175.78% — and 2023, when it soared 65.43%.
- Tracing OCGN's Free Cash Flow over 5 years: stood at -$16.6 million in 2022, then soared by 65.43% to -$5.7 million in 2023, then tumbled by 80.88% to -$10.4 million in 2024, then sank by 36.14% to -$14.1 million in 2025, then sank by 54.31% to -$21.8 million in 2026.
- The last three Free Cash Flow figures came in at -$21.8 million (Q1 2026), -$14.1 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | -12.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.22 Mn |
| Mar 31, 2026 | -21.80 Mn |
| Dec 31, 2025 | -14.00 Mn |
| Sep 30, 2025 | -13.01 Mn |
| Jun 30, 2025 | -10.77 Mn |
| Mar 31, 2025 | -19.37 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Sep 30, 2024 | -11.78 Mn |
| Jun 30, 2024 | -10.42 Mn |
| Mar 31, 2024 | -12.95 Mn |
| Dec 31, 2023 | -14.02 Mn |
| Sep 30, 2023 | -17.07 Mn |
| Jun 30, 2023 | -21.58 Mn |
| Mar 31, 2023 | -19.85 Mn |
| Dec 31, 2022 | -18.94 Mn |
| Sep 30, 2022 | -15.15 Mn |
| Jun 30, 2022 | -14.78 Mn |
| Mar 31, 2022 | -15.68 Mn |
| Dec 31, 2021 | -13.00 Mn |
| Sep 30, 2021 | -8.28 Mn |